SirT1 fails to affect p53‐mediated biological functions
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: The SirT1 gene encodes a protein deacetylase that acts on a number of nuclear substrates. p53 was identified as a SirT1 substrate whose transcriptional activity was reported to be negatively regulated by SirT1‐dependent deacetylation. We set out to determine whether developmental defects and perinatal lethality observed in SirT1‐null mice were caused by p53 hyperactivity by creating mice deficient for both SirT1 and p53. Animals null for both proteins were smaller than normal at birth, had eyelid opening defects and died during the late prenatal and early postnatal periods, a phenotype indistinguishable from mice deficient for SirT1 alone. Upon re‐examination of the role of SirT1 in modulating p53 activity, we found that while SirT1 interacts with p53, the SirT1 protein had little effect on p53‐dependent transcription of transfected or endogenous genes and did not affect the sensitivity of thymocytes and splenocytes to radiation‐induced apoptosis. These findings suggest that SirT1 does not affect many p53‐mediated biological activities despite the fact that acetylated p53 has been shown to be a substrate for SirT1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 2×
“Both p53 and SirT1 are key proteins involved in the regulation of cellular behavior. p53 is a transcription factor whose activity is thought to be modulated by acetylation (Sakaguchi et al., 1998).”
BackgroundDevelopmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice
Cheng, H.-L., Mostoslavsky, R., Saito, S., Manis, J. P., Gu, Y., Patel, P., Bronson, R., Appella, E., Alt, F. W., & Chua, K. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934713100 · Cited by 1,095 · cited 6×
“These results are difficult to reconcile with previous reports that indicate down-regulation of p53 transcriptional activity by SirT1 (Luo et al., 2001; Vaziri et al., 2001; Langley et al., 2002; Cheng et al., 2003).”
BackgroundResultInfluentialMechanism of Human SIRT1 Activation by Resveratrol
Borra, M. T., Smith, B. C., & Denu, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501250200 · Cited by 1,065 · cited 1×
“It has since been shown that resveratrol activates SirT1 in a highly substrate-specific manner (Borra et al., 2005; Kaeberlein et al., 2005), indicating that any effects observed using this compound cannot be attributed to the activation of SirT1.”
BackgroundDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“The HCT116 human colorectal carcinoma cell line and its p53-null derivative (Brattain et al., 1981; Bunz et al., 1999) were used as controls to verify that the expression from the p21 promoter was dependent on endogenous p53.”
MethodHuman SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.031 · Cited by 916
Substrate-specific activation of sirtuins by resveratrol
Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500655200 · Cited by 745
The Mammalian SIR2α Protein Has a Role in Embryogenesis and Gametogenesis
McBurney, M. W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., Webb, J. R., Lansdorp, P. M., & Lemieux, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.38-54.2003 · Cited by 611 · cited 2×
“SirT1 knockout animals were previously described (McBurney et al., 2003b).”
MethodSelf-citationModulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586
Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 2×
“Transfection assays indicated that the Cterminal lysine residues of p53 are important for modulating stability and activity but recent studies report that mutating the 6 or 7 C-terminal lysine codons of the endogenous p53 gene does not affect p53 transcriptional activity or p53-dependent processes such as cell cycle a…”
BackgroundKrummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187 · cited 2×
“Transfection assays indicated that the Cterminal lysine residues of p53 are important for modulating stability and activity but recent studies report that mutating the 6 or 7 C-terminal lysine codons of the endogenous p53 gene does not affect p53 transcriptional activity or p53-dependent processes such as cell cycle a…”
Background
Cited by
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Sirtuins in mammals: insights into their biological function
Michan, S., & Sinclair, D. (2007) · Biochemical Journal · doi:10.1042/bj20070140 · Cited by 1,718
Sirtuins in aging and age-related disease
Longo, V. D., & Kennedy, B. K. (2006) · Cell · doi:10.1016/j.cell.2006.07.002 · Cited by 628
“…activity was originally reported to inhibit apoptosis through deacetylation of p53 (Langley et al., 2002; Luo et al., 2001), more recent reports suggest that although Sirt1 can deacetylate p53 there is little effect on p53-mediated biological outcomes (Kamel et al., 2006; Solomon et al., 2006).”
BackgroundSirtuins: critical regulators at the crossroads between cancer and aging
Saunders, L. R., & Verdin, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210616 · Cited by 489
SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2
Peck, B., Chen, C.-Y., Ho, K.-K., Di Fruscia, P., Myatt, S. S., Coombes, R. C., Fuchter, M. J., Hsiao, C.-D., & Lam, E. W.-F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0971 · Cited by 433
Metadata
- Authors
- Kamel, C., Abrol, M., Jardine, K., He, X., & McBurney, M. W.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2006-01-30
- Volume
- 5
- Issue
- 1
- Pages
- 81-88
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2172011238
- Cited by
- 64
- References
- 13
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.